The FDA Cracking Down on Compounded Weight Loss Drugs – Here’s What It Means for Telehealth Companies and Consumers
After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...
Zacks Investment Research on MSN2d
Hims & Hers Stock Gains 8.6% in Three Months: How to Play It?
Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock of late. Shares of the ...
Hims & Hers: A Generational Dip-Buying Opportunity
Hims & Hers saw a massive YTD surge, but FDA news led to a pullback. Find out why HIMS stock is still undervalued and why ...
Why Novo Nordisk (NVO) Is Rising Today
Novo Nordisk (NVO) is advancing 4% after the drug maker cut the price of its very popular weight-loss drug, Wegovy, by over ...
Novo Nordisk to sell Wegovy for $499 a month to cash-paying US customers
Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to ...
Forecasting The Future: 15 Analyst Projections For Hims & Hers Health
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $37.07, along ...
Defiance Launches RKLX and HIMZ: 2X Leveraged ETFs for Rocket Lab and Hims & Hers
RKLX, the Defiance Daily Target 2X Long RKLB ETF, seeks daily investment results that correspond to twice (200%) the daily percentage change of Rocket Lab, a company at the forefront of satellite ...